RAPT Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
121
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.2B
RAPT Therapeutics General Information
Description
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Contact Information
Website
www.rapt.com(Operating Subsidiary)
Corporate Office
- 561 Eccles Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 561 Eccles Avenue
- South San Francisco, CA 94080
- United States
RAPT Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 03-Mar-2026 | $2.2B | Completed | Generating Revenue | ||
| 10. 2PO | 23-Oct-2025 | Completed | Generating Revenue | |||
| 9. PIPE | 27-Dec-2024 | Completed | Generating Revenue | |||
| 8. PIPE | 25-May-2022 | Completed | Generating Revenue | |||
| 7. 2PO | 07-Feb-2020 | Completed | Generating Revenue | |||
| 6. IPO | 01-Nov-2019 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C2) | 18-Jun-2019 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 01-Apr-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 01-Apr-2016 | $50M | $79M | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | 07-Apr-2015 | $29M | $29M | Completed | Generating Revenue |
RAPT Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 | ||||||||
| Series C | ||||||||
| Series B | 25,000,000 | $0.000100 | $0.16 | $2 | $2 | 1x | $2 | 22.25% |
| Series A | 37,509,105 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 33.38% |
RAPT Therapeutics Comparisons
Industry
Financing
Details
RAPT Therapeutics Competitors (56)
One of RAPT Therapeutics’s 56 competitors is AnaptysBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnaptysBio | Formerly VC-backed | San Diego, CA | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Agomab Therapeutics | Formerly VC-backed | Antwerp, Belgium | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
RAPT Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
RAPT Therapeutics Patents
RAPT Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026112363-A1 | Fused heterocyclic aromatic compounds and uses thereof | Pending | 21-Nov-2024 | ||
| WO-2026055519-A1 | Fused ring imidazole compounds | Pending | 06-Sep-2024 | ||
| US-20250122208-A1 | Chemokine receptor modulators and uses thereof | Pending | 06-Oct-2023 | ||
| US-20250034115-A1 | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof | Pending | 12-Jul-2023 | ||
| WO-2025015029-A1 | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof | Inactive | 12-Jul-2023 | C07D401/14 |
RAPT Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
RAPT Therapeutics Former Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AJU IB Investment | Venture Capital | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Catalyst Operating | Growth/Expansion | Minority | ||
| Celgene | Corporation | Minority | ||
| Codon Capital | Venture Capital | Minority |
RAPT Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 30, 2025
36.03 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
RAPT Therapeutics FAQs
-
When was RAPT Therapeutics founded?
RAPT Therapeutics was founded in 2015.
-
Where is RAPT Therapeutics headquartered?
RAPT Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of RAPT Therapeutics?
RAPT Therapeutics has 121 total employees.
-
What industry is RAPT Therapeutics in?
RAPT Therapeutics’s primary industry is Drug Discovery.
-
Is RAPT Therapeutics a private or public company?
RAPT Therapeutics is a Private company.
-
What is the current valuation of RAPT Therapeutics?
The current valuation of RAPT Therapeutics is .
-
What is RAPT Therapeutics’s current revenue?
The current revenue for RAPT Therapeutics is .
-
How much funding has RAPT Therapeutics raised over time?
RAPT Therapeutics has raised $737M.
-
Who are RAPT Therapeutics’s investors?
AJU IB Investment, BVF Partners, Catalyst Operating, Celgene, and Codon Capital are 5 of 20 investors who have invested in RAPT Therapeutics.
-
Who are RAPT Therapeutics’s competitors?
AnaptysBio, Marengo Therapeutics, Agomab Therapeutics, CytomX Therapeutics, and Adaptimmune Therapeutics are some of the 56 competitors of RAPT Therapeutics.
-
When was RAPT Therapeutics acquired?
RAPT Therapeutics was acquired on 03-Mar-2026.
-
Who acquired RAPT Therapeutics?
RAPT Therapeutics was acquired by GSK.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
